Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 11, 2015, Pages 1993-2001.e2

  Leroy, Vincent ^a,b   Dumortier, Jérôme ^c,d   Coilly, Audrey ^e,f,g,h   Sebagh, Mylène ^e,f,g,h   Fougerou Leurent, Claire ^i,j   Radenne, Sylvie ^k   Botta, Danielle ^l   Durand, François ^e,m   Silvain, Christine ^n,o   Lebray, Pascal ^p   Houssel Debry, Pauline ⁱ   Kamar, Nassim ^q,r,s   D'Alteroche, Louis ^t   Petrov Sanchez, Ventzislava ^u   Diallo, Alpha ^u   Pageaux, Georges Philippe ^v,w   Duclos Vallee, Jean Charles ^e,f,g,h   Duclos Vallée, Jean Charles ^w   Bellissant, Eric ^w   Botta Fridlund, Danielle ^w   Duvoux, Christophe ^w   Renault, Alain ^w   Rohel, Alexandra ^w   Roque, Anne Marie ^w   Taburet, Anne Marie ^w   Veislinger, Aurélie ^w   more..

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d UNIVERSITÉ LYON 1   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g Universite Paris Sud   (France)

^h DHU Hepatinov   (France)

ⁱ RENNES UNIVERSITY HOSPITAL   (France)

^j UNIVERSITÉ DE RENNES 1   (France)

^k CROIX ROUSSE HOSPITAL   (France)

^l HÔPITAL DE LA CONCEPTION   (France)

^m INSERM   (France)

ⁿ POITIERS UNIVERSITY HOSPITAL   (France)

^o Pôle Biologie Santé   (France)

^p PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^q CHU RANGUEIL   (France)

^r UNIVERSITÉ PAUL SABATIER   (France)

^s CHU PURPAN   (France)

^t SERVICE DE DERMATOLOGIE   (France)

^u France Recherche Nord and Sud Sida   (France)

^v HÔPITAL SAINT ELOI   (France)

^w UNIV MONTPELLIER   (France)

more..

Author keywords

Cirrhosis; DAA; NS5b Polymerase Inhibitor; Re infection

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOSPORIN; DACLATASVIR; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON ALPHA; RIBAVIRIN; SOFOSBUVIR; TACROLIMUS; VIRUS RNA; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; ASCITES; ASTHENIA; BACTERIAL PERITONITIS; BELGIUM; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CHOLESTATIC HEPATITIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FIBROSING CHOLESTATIC HEPATITIS C; FRANCE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INCIDENCE; INFECTION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIXED INFECTION; MULTICENTER STUDY; MYCOSIS; NEUTROPENIA; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RECURRENT INFECTION; SEPSIS; SURVIVAL RATE; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT DURATION; URINARY TRACT INFECTION; ADVERSE EFFECTS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MIDDLE AGED; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; BELGIUM; CHOLESTASIS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FRANCE; HEPATITIS C; HUMANS; IMIDAZOLES; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84944279226     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.05.030     Document Type: Article

References (25)

1. Merion R.M. Current status and future of liver transplantation. Semin Liver Dis 2010, 30:411-421.
2. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002, 8:S14-S18.
3. Berenguer M., Prieto M., San Juan F., et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002, 36:202-210.
4. Wiesner R.H., Sorrell M., Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003, 9:S1-S9.
5. Davies S.E., Portmann B.C., O'Grady J.G., et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991, 13:150-157.
6. Zylberberg H., Carnot F., Mamzer M.F., et al. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1997, 63:158-160.
7. Narang T.K., Ahrens W., Russo M.W. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010, 16:1228-1235.
8. Xiao S.Y., Lu L., Wang H.L. Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis. Int J Clin Exp Pathol 2008, 1:396-402.
9. Antonini T.M., Sebagh M., Roque-Afonso A.M., et al. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. Am J Transplant 2011, 11:1686-1695.
10. Duclos-Vallee J.C., Feray C., Sebagh M., et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008, 47:407-417.
11. McCashland T.M. Retransplantation for recurrent hepatitis C: positive aspects. Liver Transpl 2003, 9:S67-S72.
12. Calmus Y., Duvoux C., Pageaux G., et al. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNalpha-2a plus ribavirin. J Hepatol 2012, 57:564-571.
13. Coilly A., Roche B., Dumortier J., et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014, 60:78-86.
14. Charlton M., Gane E., Manns M.P., et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015, 148:108-117.
15. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014, 370:211-221.
16. Fontana R.J., Hughes E.A., Bifano M., et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013, 13:1601-1605.
17. Forns X., Charlton M., Denning J., et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation. Hepatology 2015, 61:1485-1494.
18. Kim B., Trivedi A., Thung S.N., et al. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation. Semin Liver Dis 2014, 34:108-112.
19. Verna E.C., Abdelmessih R., Salomao M.A., et al. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl 2013, 19:78-88.
20. Dixon L.R., Crawford J.M. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007, 13:219-226.
21. Antonini T.M., Furlan V., Teicher E., et al. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. AIDS 2015, 29:53-58.
22. Satapathy S.K., Sclair S., Fiel M.I., et al. Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation. Hepatol Res 2011, 41:328-339.
23. Duarte-Rojo A., Budhraja V., Veldt B.J., et al. Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review. Liver Transpl 2013, 19:1311-1317.
24. Graziadei I.W., Zoller H.M., Schloegl A., et al. Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation. Liver Transpl 2012, 18:671-679.
25. Kwo P.Y., Mantry P.S., Coakley E., et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014, 371:2375-2382.